Triple therapy shows promise for untreatable liver cancer

NCT ID NCT07584018

Not yet recruiting Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of two targeted drugs (donafenib and sintilimab) plus chemotherapy delivered directly to the liver as a first treatment for people with advanced liver cancer that cannot be surgically removed. The study will enroll 90 participants and measure how long the cancer stays under control. The goal is to find a more effective first-line option for this difficult-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: donafenib, sintilimab, and chemotherapy (oxaliplatin, leucovorin, fluorouracil) given via hepatic artery infusion
What this could lead to: If it works, this could offer a new first-line treatment option for people with advanced liver cancer that cannot be removed by surgery.
What could go wrong: This is an early phase 2 trial with only 90 participants, so results may not apply to everyone. The combination of drugs can cause serious side effects, and the study has not yet started recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC - HEPATOCELLULAR CARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.